Science Creates member FluoretiQ, today announced the hire of new Chief Medical Officer (CMO), Mr Kasra Saeb-Parsy, to help realise the potential of their technology.
FluoretiQ want to revolutionise the way antibiotic treatments are prescribed at point-of-care for diseases such as urinary tract infections and sexually transmitted diseases. Their platform technology aims to enable doctors to confirm infection within minutes, stopping the use of incorrect and unnecessary prescription of antibiotics.
FluoretiQ’s new CMO, Mr Kasra Saeb-Parsy is a Consultant Urologist with Cambridge (UK) University Hospitals NHS Foundation Trust. Mr. Saeb-Parsy will oversee and lead all clinical development, regulatory and medical affairs strategies and activities of the Company.
“I am delighted to welcome Kasra as our Chief Medical Officer at this key stage of our company growth as we approach clinical studies and regulatory approval in the UK and USA. Kasra brings over 21 years of clinical and patient care experience and has a fine track record as a clinical researcher”.
“Kasra’s experience in advising hospitals on urology practice and network of GPs, who are one of the key markets for our future products, are great assets to the development of our business.”
Neciah Dorh CEO of FluoretiQ Ltd.
FluoretiQ’s platform is called NANOPLEX and has the potential to identify and enumerate bacteria at the point-of-care. Mr Saeb-Parsy explains “The work carried out by FluoretiQ using their NANOPLEX technology platform paves the way for rapid and accurate diagnosis of UTIs and the identification of the causative organism. This allows more appropriate and tailored antibiotic use rather than our current practice of initiating antibiotics whilst awaiting the results of microscopy and culture which can often take up to 72 hours or longer.“
About Mr Kasra Saeb-Parsy
Mr Kasra Saeb-Parsy is a Consultant Urologist at Cambridge University Hospitals and Emergency Urology lead as well as National Urology Advisor for Nuffield Health. Kasra has extensive experience in basic science research as well clinical research. He has a particular interest in novel approaches to rapid diagnosis of diseases and in setting up and leading clinical trials, particularly in the field of bladder cancer.
To find out more about FluoretiQ, visit their website.
Science Creates Ventures (FRN: 933134) is an Appointed Representative of Kin Capital Partners LLP “KCP”, which is authorised and regulated by the Financial Conduct Authority (FRN: 656789).